Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Opposition Parties Submit Bill to Scrap Off-Year Drug Price Revisions
Two Japanese opposition parties submitted a lawmaker-sponsored bill effectively aimed at abolishing “off-year” drug price revisions to the Diet on December 20. Currently, there are no legal rules that set the timing of revisions for reimbursement fees including drug prices.…
To read the full story
Related Article
- Nippon Ishin Co-Leader Shows Understanding of Off-Year Price Revisions
April 11, 2025
- Bill to Nix Off-Year Scheme Politicized, Could Clear Lower House with Ishin Support
April 10, 2025
- DPP to Co-Sponsor Bill to Make Drug Price Revisions a Biennial Event
December 18, 2024
- CDP OKs Bill to Scrap Off-Year Revisions, Aims for Diet Submission Soon
December 13, 2024
- Opposition CDP Eyes Nonpartisan Bill to Scrap Off-Year Drug Price Revisions
November 14, 2024
- Japan Political Parties Push Varied Pharma Policies as Election Campaign Kicks Off
October 15, 2024
REGULATORY
- Japan to Designate International Clinical Trial Hubs in FY2027
August 28, 2026
- MHLW Tax Reform Requests Cover Support for MCM Preparedness
August 28, 2026
- Patient Group Flags Risks of Inconsistent Decisions on OTC-Like Drug Charges
August 28, 2026
- MHLW Pharma Bureau Eyes 12 Billion Yen to Boost Plasma Product Production
August 28, 2026
- Novo, Lilly Want Reimbursement Support for Obesity Care: LDP Hearing
August 28, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…